摘要
嵌合抗原受体T细胞(CAR-T),是目前肿瘤免疫细胞疗法研究的热点,其在治疗血液系统恶性肿瘤上的成就有目共睹,但其针对实体瘤的治疗仍存在着些许问题和挑战。目前关于CAR-T治疗实体瘤的挑战主要有肿瘤抗原的异质性或抗原逃逸、CAR-T细胞归巢障碍、肿瘤免疫抑制性微环境、脱靶效应、CAR-T细胞毒性等问题。针对这些挑战也相应出现了一些应对策略,如cocktail CAR-T细胞、局部输注CAR-T细胞、阻断免疫抑制性信号、SynNotch CAR-T等方法。本文阐述围绕目前CAR-T技术治疗实体肿瘤存在的挑战及应对策略。
Chimeric antigen receptor T cell(CAR-T)is currently the research focus of tumor immune cell therapy.Its achievements in the treatment of hematological malignancies are obvious to all,but there are still some problems and challenges in the treatment of solid tumors.At present,the main challenges in CAR-T treatment of solid tumors include tumor antigen heterogeneity or antigen escape,CAR-T cell homing barrier,tumor immunosuppressive microenvironment,off-target effect,and CAR-T cell toxicity.In response to these challenges,some coping strategies have emerged,such as cocktail CAR-T cells,local infusion of CAR-T cells,blocking immunosuppressive signals,SynNotch CAR-T and other methods.This article reviews the current challenges and strategies of CAR-T technology in the treatment of solid tumors.
作者
杨小慧
崔代迅
冯振卿
Yang Xiaohui;Cui Daixun;Feng Zhenqing(Department of Pathology,School of Basic Medicine,Nanjing Medical University,National Health Commission Key Laboratory of Antibody Techniques,Nanjing Medical University,Nanjing 211166,China)
出处
《中华转移性肿瘤杂志》
2024年第3期195-201,共7页
Chinese Journal of Metastatic Cancer
基金
国家自然科学基金(82073389)。
